Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Fundamentals of Market Access for Pharmaceuticals
”Because at the heart of the apparent conflict between public health concerns and capitalistic interests, market access for pharmaceuticals is largely driven by political considerations, the difference with usual consumer goods being that pharmaceuticals are saving lives or years of life in good health”. If pharmaceutical companies are to innovate, they must be incentivised with prices that reflect the value of their products, and the resources and risks involved in their production. To ensure appropriate access to new drugs and treatments for patients in need around the world, affordability is key. How do we tackle this dilemma? This question is critical for all stakeholders. The develo...
From Genetics to Quality of Life
Bronchial asthma is much more a syndrome than a true disease; as a science, asthmology covers a large area from Genetics to Quality of life. Asthma management is changing; new drugs are available and have to be included in the guidelines; moreover education has to be done in order to improve the quality of life of our patients. Pharmaco-economic parameters have to be better understood to propose the best strategies to the majority of patients. In the future, genetics could be interesting for diagnosis, probably prognosis and treatment; however, this is not the case today. The main objective for the clinician is to evaluate a perfect phenotype to make the genetic studies clearly understandable. The key group behind this book is Interasma, a society of asthma specialists which has been functioning as a worldwide association for over 40 years, and which is directly focussed on the prevention and treatment of asthma.
Place de la prévention dans la politique de santé
Cette étude sur la réalité de la prévention dans la politique de santé s'est articulée en deux parties. - La première, après avoir essayé de cadrer cette question, d'en définir les différents acteurs et de faire une estimation des dépenses qui lui sont imparties, a été consacrée à ce qu'en pensent les acteurs et décideurs du système de santé. - La seconde, après avoir abordé un des points clés de la politique de prévention qui est la question des inégalités sociales de santé, a envisagé le développement des pratiques préventives, leur financement et leur insertion dans une politique globale qui intègre des impératifs d'équité, de qualité et d'efficience, en s'appuyant sur des exemples concrets tels le tabac, les vaccins et les comportements sexuels à risque. [Extr. site web JL Eurotext]
Oncology
None
